Published in Lab Law Weekly, April 10th, 2009
As of March 17, 2009 three (3) of the thirteen (13), or twenty-three percent (23%), evaluable patients in the Phase I clinical trial continue to survive beyond the historical median survival of six (6) months (180 days) or less, based on the National Cancer Institute's Gynecologic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.